MaxCyte, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MXCT research report →
Companymaxcyte.com
MaxCyte, Inc. , a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
- CEO
- Maher Masoud
- IPO
- 2021
- Employees
- 114
- HQ
- Rockville, MD, US
Price Chart
Valuation
- Market Cap
- $114.62M
- P/E
- -2.92
- P/S
- 3.55
- P/B
- 0.68
- EV/EBITDA
- -3.26
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 80.70%
- Op Margin
- -119.73%
- Net Margin
- -121.16%
- ROE
- -22.03%
- ROIC
- -20.82%
Growth & Income
- Revenue
- $33.03M · -14.50%
- Net Income
- $-44,630,000 · -8.71%
- EPS
- $-0.42 · -7.69%
- Op Income
- $-45,285,000
- FCF YoY
- -23.64%
Performance & Tape
- 52W High
- $2.40
- 52W Low
- $0.64
- 50D MA
- $0.83
- 200D MA
- $1.25
- Beta
- 1.57
- Avg Volume
- 987.86K
Get TickerSpark's AI analysis on MXCT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 15, 26 | Ahuja Parmeet | other | 187,500 |
| Mar 30, 26 | Ahuja Parmeet | other | 375,000 |
| Mar 30, 26 | Ahuja Parmeet | other | 0 |
| Mar 27, 26 | Masoud Maher | other | 600,000 |
| Mar 27, 26 | Masoud Maher | other | 300,000 |
| Mar 17, 26 | Swirsky Douglas J | sell | 10,142 |
| Jun 25, 25 | Hemrajani Rekha | sell | 10,684 |
| Aug 13, 25 | Swirsky Douglas J | buy | 50,000 |
| Aug 13, 25 | Masoud Maher | buy | 75,000 |
| Aug 13, 25 | Erck Stanley C | buy | 100,000 |
Our MXCT Coverage
We haven't published any research on MXCT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MXCT Report →